Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

Clinical trial NCT04616560 · RECRUITING

Trial details

NCT number: NCT04616560
Sponsor: National Cancer Institute (NCI)
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Desmoplastic Small Round Cell Tumor Osteosarcoma Recurrent Desmoplastic Small Round Cell Tumor Recurrent Kidney Wilms Tumor Recurrent Osteosarcoma Refractory Desmoplastic Small Round Cell Tumor Refractory Wilms Tumor Wilms Tumor

Start date: 2021-03-08
Primary completion: 2027-12-31
Enrollment: 55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.